<DOC>
	<DOCNO>NCT00568841</DOCNO>
	<brief_summary>This Phase-II Study evaluate accuracy Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography ( FDG-/FLT-PET ) analyse early prediction non-progression patient non-small-cell lung cancer ( NSCLC ) treat Erlotinib .</brief_summary>
	<brief_title>Erlotinib Sequential Positron Emission Tomography ( PET ) Advanced Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written inform consent â‰¥ 18 year age Untreated nonsmallcell lung cancer stage IIIB/IV Life expectancy &gt; 3 month Performance status ECOG 02 Concurrent systemic immune therapy , chemotherapy therapy anticancer drug indicate study protocol Any investigational agent ( ) within 4 week prior study entry Previous administration EGFRtargeted therapy ( antibody , small molecule others ) Any medical , mental psychological condition opinion investigator would permit patient complete study understand patient information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>advanced Non-Small-Cell Lung Cancer</keyword>
	<keyword>erlotinib</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>FLT-PET</keyword>
</DOC>